Nerve growth factor signaling in prostate health and disease

Growth Factors

Volumn 28, Issue 3, 2010, Pages 191-201

  Arrighi, Nicola ^a   Bodei, Serena ^a   Zani, Danilo ^a   Simeone, Claudio ^a   Cunico, Sergio Cosciani ^a   Missale, Cristina ^a   Spano, Pierfranco ^a   Sigala, Sandra ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Cancer; Nerve growth factor; Nerve growth factor receptors; Prostate

Indexed keywords

CEP 751; FLURBIPROFEN; GENISTEIN; GONADORELIN; GONADORELIN AGONIST; LESTAURTINIB; MORPHINE; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY; NERVE GROWTH FACTOR RECEPTOR; NEUROTROPHIN RECEPTOR P75; PROTEIN TYROSINE KINASE A; TANEZUMAB;

ADD ON THERAPY; ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; APOPTOSIS; ARTICLE; BONE PAIN; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; MALE; METASTASIS; MITOGENESIS; NONHUMAN; PAIN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; HUMANS; MALE; NERVE GROWTH FACTOR; PAIN; PROSTATE; PROSTATIC NEOPLASMS; RECEPTOR, TRKA; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; WOUNDS AND INJURIES;

EID: 77952480076     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977190903578678     Document Type: Article

References (102)

1. Abdiche YN, Malashock DS, Pons J. 2008. Probing the binding mechanism and affinityof tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci 17:1326-1335.
2. Aloe L, Cossari C, Callissano P, Levi-Montalcini R. 1981. Somatic and behavioral postnatal effects of fetal injections of nerve growth factor antibodies in the rat. Nature 291:413-415.
3. Ayer-LeLievre C, Olson L, Ebendal T, Hallbõõk F, Persson H. 1988. Nerve growth factor mRNA and protein in the testis and epididymis of mouse and rat. Proc Natl Acad Sci USA 85:2628-2632.
4. Banerjee S, Li Y, Wang Z, Sarkar FH. 2008. Multi-targeted therapy of cancer by genistein. Cancer Lett 269:226-242.
5. Barker PA. 2004. P75 is positively promiscuous: Novel partners and new insights. Neuron 42:529-533.
6. Barker PA. 2007. High affinity not in the vicinity? Neuron 53:1-4.
7. Bibel M, Barde YA. 2000. Neurotrophin: Key regulators of cell fate and cell shape in the vertebral nervous system. Genes Dev 14:2919-2937.
8. Bibel M, Hoppe H, Barde YA. 1999. Biochemical and functional interactions between the neurotrophin receptors trk and p75NTR. EMBO J 18:616-622.
9. Bilderback TR, Gazula VR, Dobrowsky R. 2001. Phosphoinositide 3-kinase regulates crosstalk between TrkA tyrosine kinase and p75 (NTR) -dependent sphingolipid signaling pathways. J Neurochem 76:1540-1551.
10. Blochl A, Blochl R. 2007. A cell-biological model of p75NGFR signaling. J Neurochem 102:289-305.
11. Bradshaw RA, Murray-Rust J, Ibanez CF, McDonald NQ, Lapatto R, Blundell TL. 1994. Nerve growth factor: Structure/function relationships. Protein Sci 3:1901-1913.
12. Bredesen DE, Rabizadeh S. 1997. p75NTR ad apoptosis: Trk-dependent and Trk-independent effects. Trends Neurosci 20:287-290.
13. Casademunt E, Carter BD, Benzel I, Frade JM, Dechant G, Barde YA. 1999. The zinc finger protein NRIF interacts with the neurotrophin receptor p75 (NTR) and participates in programmed cell death. EMBO J 18:6050-6061.
14. Castellon E, Clementi M, Hitschfeld C, Sanchez C, Benitez D, Sachenz L, Contreras H, Huidobro C. 2006. Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest 24:261-268.
15. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E. 2002. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94:1099-1106. (Pubitemid 34830730)
16. Chao MV. 2003. Neurotrophins and their receptors: A convergence point for many signalling pathways. Nat Rev Neurosci 4:299-309.
17. Chao M, Bothwell M. 2002. Neurotrophins: To cleave or not to cleave. Neuron 33:9-12.
18. 53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas. Prostate 69:1025-1033.
19. Clinical Trials [Internet]. Identifier: NCT00545129: A Study of Tanezumab as Add-On Therapy to Opioid Medication in Patients with Pain Due to Cancer that has Spread to Bone. Lister Hill National Center for Biomedical Communications, US National Library of Medicine, US National Institutes of Health. Available from www.clinicaltrials.gov.
20. Delsite R, Djakiwe D. 1996. Anti-proliferative effect of the kinases inhibitors K252a on human prostatic carcinoma cell line. J Androl 17:481-490.
21. Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S, George D, Isaacs JT. 1998. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res 4:1887-1898.
22. Djakiew D. 1992. Role of nerve growth factor-like protein in the paracrine regulation of prostate growth. J Androl 13:476-487.
23. Djakiew D. 2000. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 42:150-160.
24. Djakiew D, Delsite R, Pflug B, Wrathall J, Lynch JH, Onoda M. 1991. Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. Cancer Res 51:3304-3310.
25. Djakiew D, Pflug B, Onoda M. 1993. Stromal-epithelial paracrine interactions in the neoplastic rat and human prostate. Adv Exp Med Biol 330:185-202.
26. Djakiew D, Delsite R, Dalal R, Pflug B. 1996. The role of the low affinity nerve growth factor receptor and the high affinity Trk receptor in human prostate carcinogenesis. Radiat Oncol Investig 3:333-339.
27. Dollé L, Adriaenssens E, El Yazidi-Belkoura I, Le Bourhis X, Nurcombe V, Hondermarck H. 2004. Nerve growth factor receptors and signaling in breast cancer. Curr Cancer Drug Targets 4:463-470.
28. Engel JB, Schally AV. 2007. Drug Insight: Clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 3:157-167.
29. Festuccia C, Muzi P, Gravina GL, Millimaggi D, Speca S, Dolo V, Ricevuto E, Vicentini C, Bologna M. 2007. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro. Int J Oncol 30:193-200.
30. Fiorentini C, Facchetti M, Finardi A, Sigala S, Páez-Pereda M, Sher E, Spano P, Missale C. 2002. Nerve growth factor and retinoic acid interactions in the control of small cell lung cancer proliferation. Eur J Endocrinol 4147:371-379.
31. Freund-Michel V, Frossard N. 2008. The nerve growth factor and its receptors in airway inflammatory diseases. Pharmacol Ther 117:52-76.
32. Geetha T, Jiang J, Wooten MW. 2005. Lysine 63 polyubiquitination of the nerve growth factor receptor TrkA directs internalization and signaling. Mol Cell 20:301-312.
33. Geldof AA, van Haarst EP, Newling DWW. 1998. Neurotrophic factors in prostate and prostatic cancer. Prostate Cancer Prostatic Dis 1:236-241.
34. Graham CW, Lynch JH, Djakiew D. 1992. Distribution of nerve growth factor-like protein and nerve growth factor receptors in human benign prostatic hyperplasia and prostatic adenocarcinoma. J Urol 147:1444-1447.
35. He XL, Garcia KC. 2004. Structure of nerve growth factor complexed with the shared neurotrophin receptor p75. Science 304:870-875.
36. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F. 2008. European Association of Urology 2008. EAU guidelines on prostate cancer. Eur Urol 53:68-80.
37. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu MT, Mirand EA, Munphy GP. 1983. LNCaP model of human prostatic carcinoma. Cancer Res 43:1809-1818.
38. Howe CL, Mobley WC. 2005. Long-distance retrograde neurotrophic signaling. Curr Opin Neurobiol 15:40-48.
39. Jimenez-Andrade JM, Martin CD, Koewler NJ, Freeman KT, Sullivan LJ, Halvorson KG, Barthold CM, Peters CM, Buus RJ, Ghilardi JR, Lewis JL, Kuskowski MA, Mantyh PW. 2007. Nerve growth factor sequestering therapy attenuates nonmalignant skeletal pain following fracture. Pain 33:183-196.
40. Johnson D, Lanahan A, Buck CR, Sehgal A, Morgan C, Mercer E, Bothwell M, Chao M. 1986. Expression and structure of the human NGF receptor. Cell 47:545-554. (Pubitemid 17215345)
41. Khwaja F, Tabassum A, Allen J, Djakiew D. 2006. The p75NTR tumor suppressor induces cell cycle arrest facilitating caspase mediated apoptosis in prostate tumor cells. Biochem Biophys Rews Commun 341:1184-1192.
42. Khwaja F, Quann EJ, Pattabiraman N, Wynne S, Djakiew D. 2008. Carprofen induction of p75NTR-dependent apoptosis via the p38 mitogen-activated protein kinase pathway in prostate cancer cells. Mol Cancer Ther 7:43539-3545.
43. Khwaja F, Wynne S, Posey I, Djakiew D. 2009. 3, 3'-Diindolylmethane induction of p75NTR-dependent cell death via the p38 mitogen-activated protein kinase pathway in prostate cancer cells. Cancer Prev Res 2:566-571.
44. Koewler NJ, Freeman KT, Buus RJ, Herrera MB, Jimenez-Andrade JM, Ghilardi JR, Peters CM, Sullivan LJ, Kuskowski MA, Lewis JL, Mantyh PW. 2007. Effects of a monoclonal antibody raised against nerve growth factor on skeletal pain and bone healing after fracture of the C57BL/6J mouse femur. J Bone Miner Res 22:1732-1742.
45. Krũttgen A, Schneider I, Weis J. 2006. The dark side of the NGF family: neurotrophins in neoplasias. Brain Pathol 16:304-310.
46. Krygier S, Djakiew D. 2001. Molecular characterization of the loss of p75 (NTR) expression in human prostate tumor cells. Mol Carcinog 31:46-55.
47. Krygier S, Djakiew D. 2002. Neurotrophin receptor p75NTR suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells. Int J Cancer 98:1-7.
48. Levi-Montalcini R. 1987. The nerve growth factor 35 years later. Science 237:1154-1162.
49. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A. 1996. Nerve growth factor: From neurotrophin to neurokine. Trends Neurosci 19:514-520.
50. Li C, Watanabe G, Weng Q, Jin W, Furuta C, Suzuki AK, Kawaguchi M, Taya K. 2005. Expression of nerve growth factor (NGF), and its receptors TrkA and p75 in the reproductive organs of the adult male rats. Zoolog Sci 22:933-937.
51. Mach DB, Rogers SD, Sabino MC, Luger NM, Schwei MJ, Pomonis JD, Keyser CP, Clohisy DR, Adams DJ, O'Leary P, Mantyh PW. 2002. Origins of skeletal pain: Sensory and sympathetic innervation of the mouse femur. Neuroscience 113:155-166.
52. Makkerh JP, Ceni C, Auld DS, Vaillancourt F, Dorval G, Barker PA. 2005. p75 neurotrophin receptor reduces ligand-induced Trk receptor ubiquitination and delays Trk receptor internalization and degradation. EMBO Rep 6:936-941.
53. Marelli MM, Moretti RM, Dondi D, Motta M, Limonta P. 1999. Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells. Endocrinology 140:329-334.
54. Martin-Zanca D, Oskam R, Mitra G, Copeland T, Barbacid M. 1989. Molecular and biochemical characterization of the human trk proto-oncogene. Mol Cell Biol 9:24-33.
55. Martínez-Serrano A, Olsson M, Gates MA, Bjõrklund A. 1998. In utero gene transfer reveals survival effects of nerve growth factor on rat brain cholinergic neurones during development. Eur J Neurosci 710:263-271.
56. McDonald NQ, Lapatto R, Murray-Rust J, Gunning J, Wlodawer A, Blundell TL. 1991. New protein fold revealed by a 2.3-A resolution crystal structure of nerve growth factor. Nature 354:411-414.
57. McGrogan D, Saint-Andrè JP, Dicou E. 1992. Expression of nerve growth factor receptor gene in human tissue and in prostatic adenocarcinoma cell line. J Neurochem 59:1381-1391.
58. McMahon SB, Bennett DL, Priestley JV, Shelton DL. 1995. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule. Nat Med 1:774-780.
59. Meakin SO, Shooter EM. 1992. The nerve growth factor family of receptors. Trends Neurosci 15:323-331.
60. Missale C, Boroni F, Losa M, Giovanelli M, Zanellato A, Dal Toso R, Balsari A, Spano P. 1993. Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc Natl Acad Sci USA 90:7961-7965.
61. Missale C, Codignola A, Sigala S, Finardi A, Paez-Pereda M, Sher E, Spano PF. 1998. Nerve growth factor abrogates the tumorigenicity of human small cell lung cancer cell lines. Proc Natl Acad Sci USA 95:5366-5371.
62. Montano X, Djamgoz MB. 2004. Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer. FEBS Lett 571:1-8.
63. Moretti RM, Marelli MM, Dondi D, Poletti A, MartiniL, Motta M, Limonta P. 1996. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab 81:3930-3937.
64. Moul JW. 2003. Population screening for prostate cancer and emerging concepts for young men. Clin Prostate Cancer 2:87-97.
65. Mouravier V, Mayes JM, Polascik TJ. 2009. Pathologic basis of focal therapy for early-stage prostate cancer. Nat Rev Urol 6:205-215.
66. Nalbandian A, Djakiew D. 2006. The p75NTR metastasis suppressor inhibits urokinases plasminogen activator, matrix metalloprotease 2 and matrix metalloprotease 9 in PC3 prostate cancer cell. Clin Exp Metastasis 23:107-116.
67. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu S-M, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. 1997. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 3:42493-2500.
68. Nico B, Mangieri D, Benagiano V, Crivellato E, Ribatti D. 2008. Nerve growth factor as an angiogenic factor. Microvasc Res 75:135-141.
69. Ohnuki Y, Marnell MM, Bobcock MS, Lechner JF, Kaighn E. 1980. Chromosomal analysis of human prostatic adenocarcinoma cell lines. Cancer Res 40:524-534.
70. Papatsoris AG, Lioltsia D, Deliveliotis C. 2007. Manipulation of the nerve growth factor network in prostate cancer. Expert Opin Investig Drugs 16:303-309.
71. Paul AB, Grant ES, Habib FK. 1996. The expression and localisation of beta-nerve growth factor (beta-NGF) in benign and malignant human prostate tissue: Relationship to neuroendocrine differentiation. Br J Cancer 74:1990-1996.
72. Perez M, Regan T, Pflug B, Lynch J, Djakiew D. 1997. Loss of the low affinity nerve growth factor receptor during malignant transformation of the human prostate. Prostate 30:274-279.
73. Pflug B, Djakiew D. 1998. Expression of p75NTR in a human prostate epithelial tumor cell line reduces nerve growth factor-induced by activation of programmed cell death. Mol Carcinog 23:107-114.
74. Pflug BR, Onoda M, Lynch JH, Djakiew D. 1992. Reduced expression of the low affinity nerve growth factor receptor in benign and malignant human prostate tissue and loss of expression in four human metastatic prostate tumor cell lines. Cancer Res 52:5403-5406.
75. Pflug BR, Dionne C, Kaplan DR, Lynch J, Djakiew D. 1995. Expression of a Trk high affinity nerve growth factor receptor in the human prostate. Endocrinology 136:262-268.
76. Pomerantz M, Kantoff P. 2007. Advances in the treatment of Prostate cancer. Ann Rev Med 58:472-479.
77. Páez Pereda M, Missale C, GrüTbler Y, Arzt E, Schaaf L, Stalla GK. 2000. Nerve growth factor and retinoic acid inhibit proliferation and invasion in thyroid tumor cells. Mol Cell Endocrinol 167:99-106.
78. Quann EJ, Khwaja F, Djakiew D. 2007a. The p38 MAPK pathway mediates aryl propionic acid induced messenger RNA stability of p75 NTR in prostate cancer cells. Cancer Res 67:11402-11410.
79. Quann EJ, Khwaja F, Zavitz KH, Djakiew D. 2007b. The aryl propionic acid R-flurbiprofen selectively induces p75-dependent decreased survival of prostate tumor cells. Cancer Res 67:3254-3262.
80. Rahbek UL, Dissing S, Thomassen C, Hansen AJ, Tritsaris K. 2005. Nerve growth factor activates aorta endothelial cells causing PI3K/Akt- and ERK-dependent migration. Pflugers Arch Eur J Physiol 450:355-361.
81. Renehan AG, O'Dwyer ST, Shalet SM. 2004. Insulin-like growth factor (IGF) -I, IGF binding protein-3, and cancer risk: Systemic review and metaregression analysis. Lancet 363:1346-1353.
82. Riccio A, Pierchala BA, Ciarallo CL, Ginty DD. 1997. An NGF-TrkA-mediated retrograde signal to transcription factor CREB in sympathetic neurons. Science 277:1097-1100.
83. Sanchez C, Clementi M, Benitez D, Contreras H, Huidobro C, Castellon E. 2005. Effect of GnRH analogs on the expression of TrkA and p75 neurotrophin receptors in primary cultures for human prostate adenocarcinoma. Prostate 65:195-202.
84. Sarker D, Reid AH, Yap TA, de Bono JS. 2009. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 15:4799-4805.
85. Segal RA, Greenberg ME. 1996. Intracellular signaling pathways activated by neurotrophic factor. Annu Rev Neurosci 19:463-489.
86. Seidl K, Holstein AF. 1990. Evidence for the presence of nerve growth factor (NGF) and NGF receptors in human testis. Cell Tissue Res 261:549-554.
87. Shonukan O, Bagayogo I, McCrea P, Chao M, Hempstead B. 2003. Neurotrophin-induced melanoma cell migration is mediated through the actin-bundling protein fascin. Oncogene 22:3616-3623.
88. Sigala S, Faraoni I, Botticini D, Paez-Pereda M, Missale C, Bonmassar E, Spano P. 1999. Suppression of telomerase, reexpression of KAI 1 and abrogation of tumorigenity by nerve growth factor in rpostae cancer cell lines. Clin Cancer Res 5:1211-1218.
89. Sigala S, Tognazzi N, Rizzetti MC, Faraoni I, Missale C, Bonmassar E, Spano P. 2002. Nerve growth factor induces the reexpression of functinal androgen receptor and p75NGFR in the androgen-insensitive prostate cancer cell line DU 145. Eur J Endocrinol 147:407-415.
90. Sigala S, Bodei S, Missale C, Zani D, Simeone C, Cunico SC, Spano PF. 2008. Gene expression profile of prostate cancer cell line: Effect of nerve growth factor treatment. Mol Cell Endocrinol 284:11-20.
91. Silha JV, Sheppard PC, Mishra S, Gui Y, Schwartz J, Dodd JG, Murphy LJ. 2006. Insulin-like growth factor (IGF) binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms. Endocrinology 147:2112-2121.
92. Sortino MA, Condorelli F, Vancheri C, Vancheri C, Chiarenza A, Bernardini R, Consoli U, Canonico PL. 2000. Mitogenic effects of NGF in LCNaP prostate adenocarcinoma cells: Role of the high and low affinity NGF receptors. Mol Endocrinol 14:124-136.
93. Stone HR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. 1978. Isolation of a human prostate carcinoma cell line (DU145). Int J Cancer 21:274-281.
94. Tacconelli A, Farina AR, Caprabianca L, de Sanctis G, Tessitore G, Vetuschi A, Sferra R, Rucci N, Argenti B, Screpanti I, Giulino A, Mackay AR. 2004. TrkA alternative splicing: A regulated tumorpromoting switch in human neuroblastoma. Cancer Cell 6:347-360.
95. Vinores SA, Perez-Polo JR. 1983. Nerve growth factor and neural oncology. Neurosci Res 9:81-100.
96. Watson JJ, Allen SJ, Dawbarn D. 2008. Targeting nerve growth factor in pain: What is the therapeutic potential? BioDrugs 22:349-359.
97. Weeraratna AT, Arnold JT, George DJ, DeMarzo A, Isaacs JT. 2000. Rational basis for Trk inhibition therapy for prostate cancer. Prostate 45:140-148.
98. Wehrman T, He X, Raab B, Dukipatti A, Blau H, Garcia KC. 2007. Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors. Neuron 53:25-38.
99. Weier HU, Rhein AP, Shadravan F, Collins C, Polikoff D. 1995. Rapid physical mapping of the human trk protooncogene (NTRK1) to human chromosome 1q21-q22 by P1 clone selection, fluorescence in situ hybridization (FISH), and computer-assisted microscopy. Genomics 26:390-393.
100. Yeiser EC, Rutkoski NJ, Naito A, Inoue J, Carter BD. 2004. Neurotrophin signalling through the p75 receptor is deficient in traf6-/- mice. J Neurosci 24:10521-10529.
101. Zampieri N, Chao M. 2004. The p75 NGF receptor exposed. Science 304:833-834.
102. Zhou J, Scholes J, Hsieh JT. 2001. Signal transduction targets in androgen-independent prostate cancer. Cancer Metastasis Rev 20:351-362.